ANP initiates ATL1102 Phase II clinical trial in DMD
Filed with ASX · · 2 pages · English
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- ATL1103/atesidorsen Early Access Program Progress Update
- ATL1103 Phase II trial results published in leading journal
- Response to ASX Price & Volume Query
- $5 Million Capital Raising Completion
- Entitlement Offer Booklet
Later from Percheron Therapeutics
- First Patient Dosed in Phase II DMD Clinical Trial
- Full Year Statutory Accounts
- Response to ASX Price and Volume Query
- Pause in trading
- Placement to Accelerate Development of ATL1102 in DMD
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics